Sigvotatug Vedotin for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 15 May 2020: Trial registered, NCT04389632
  2. 8 Jun 2020: Trial started, NCT04389632
  3. 12 Aug 2024: Trial registered, NCT06549816
  4. 21 Aug 2024: Trial started, NCT06549816

The trials

NCT04389632: A Study of Sigvotatug Vedotin in Advanced Solid Tumors

State
Under way
Phase
Phase 1
People
1,006 planned
Started
8 Jun 2020
Primary completion
16 Jun 2027
Arms
Part A: Dose escalation, Part B: Dose expansion
Results
None posted
  1. 15 May 2020: Trial registered
  2. 8 Jun 2020: Trial started

NCT06549816: A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

State
Completed
Phase
Phase 1
People
6 taking part
Started
21 Aug 2024
Primary completion
18 Nov 2025
Arms
sigvotatug vedotin
Results
None posted
  1. 12 Aug 2024: Trial registered
  2. 21 Aug 2024: Trial started
  3. 18 Nov 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.